As a consequence, autosomal dominant inherited diseases such as OPMD require a gene therapy approach that knocks down or inhibits the pathogenic protein (that is, PABPN1) and also has the ability to induce expression of a functional version of the same gene. The gene discussed is PABPN1; the disease is oculopharyngeal muscular dystrophy.